David Laidley

771 total citations
32 papers, 456 citations indexed

About

David Laidley is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, David Laidley has authored 32 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in David Laidley's work include Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Lung Cancer Research Studies (9 papers). David Laidley is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Lung Cancer Research Studies (9 papers). David Laidley collaborates with scholars based in Canada, United States and Australia. David Laidley's co-authors include Shuo Li, Dale Corbett, Yunliang Cai, Mark Landis, Anat Kornecki, Andrea Lum, Shirley Granter‐Button, Jeff Biernaskie, Aleksandra Szymanska and Stephanie Leung and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

David Laidley

28 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Laidley Canada	11	168	153	143	104	85	32	456
Yunyan Zhang Canada	15	95 0.6×	74 0.5×	67 0.5×	258 2.5×	52 0.6×	57	745
Jianguo Xu China	15	99 0.6×	50 0.3×	55 0.4×	157 1.5×	54 0.6×	62	557
Susanne Gellißen Germany	16	395 2.4×	205 1.3×	52 0.4×	296 2.8×	83 1.0×	46	827
Lara Harrison Finland	11	80 0.5×	67 0.4×	40 0.3×	294 2.8×	68 0.8×	14	560
Long Di United States	14	137 0.8×	100 0.7×	42 0.3×	104 1.0×	108 1.3×	44	530
Wojciech Ambrosius Poland	13	155 0.9×	157 1.0×	55 0.4×	51 0.5×	49 0.6×	28	541
Teresa Perillo Italy	12	66 0.4×	52 0.3×	60 0.4×	239 2.3×	46 0.5×	45	531
Yuyun Xu China	16	66 0.4×	61 0.4×	49 0.3×	279 2.7×	95 1.1×	50	601
Aly Valliani United States	10	60 0.4×	25 0.2×	130 0.9×	54 0.5×	113 1.3×	24	485
Yingmin Chen China	14	70 0.4×	62 0.4×	28 0.2×	103 1.0×	74 0.9×	40	474

Countries citing papers authored by David Laidley

Since Specialization

Citations

This map shows the geographic impact of David Laidley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Laidley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Laidley more than expected).

Fields of papers citing papers by David Laidley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Laidley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Laidley. The network helps show where David Laidley may publish in the future.

Co-authorship network of co-authors of David Laidley

This figure shows the co-authorship network connecting the top 25 collaborators of David Laidley. A scholar is included among the top collaborators of David Laidley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Laidley. David Laidley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fakir, Hatim, Lucas C. Mendez, Andrew Warner, et al.. (2025). PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial. International Journal of Radiation Oncology*Biology*Physics. 123(2). 395–405.

Yu, Evan Y., Vivek Narayan, Giuseppe Esposito, et al.. (2024). 1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW. Annals of Oncology. 35. S967–S968. 1 indexed citations

Loree, Jonathan M., David Chan, Jonathan Koea, et al.. (2024). Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs. JAMA Oncology. 10(12). 1707–1707. 2 indexed citations

Mendez, Lucas C., David Laidley, Madeleine Moussa, et al.. (2023). The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).. BMC Cancer. 23(1). 362–362. 6 indexed citations

Liu, Wei, Andrew Loblaw, David Laidley, et al.. (2022). Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol. Frontiers in Oncology. 12. 863848–863848. 5 indexed citations

Ortega, Claudia, Rebecca Wong, Patrick Veit‐Haibach, et al.. (2021). Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine. 62(10). 1406–1414. 55 indexed citations

Sartor, Oliver, David Laidley, Frédéric Pouliot, et al.. (2021). A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).. Journal of Clinical Oncology. 39(6_suppl). TPS187–TPS187. 3 indexed citations

Sutherland, Duncan E. K., Rami M. Abazid, Amol Mujoomdar, et al.. (2021). Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). Journal of Cancer Research and Clinical Oncology. 148(1). 225–236. 21 indexed citations

Sutherland, Duncan E. K., et al.. (2021). Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified AdministeredActivity Protocol in NETs of Variable Origin – A Phase 2 RegistryStudy. Current Radiopharmaceuticals. 15(2). 123–133. 3 indexed citations

10.

Rachinsky, Irina, et al.. (2020). Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer. Journal of Thyroid Research. 2020. 1–9. 5 indexed citations

11.

Wang, Shengnan, Robert Z. Stodilka, James Warrington, et al.. (2020). Evaluation of an incidental solid renal mass during cardiac Tc-99m MIBI SPECT/CT imaging. Journal of Nuclear Cardiology. 28(2). 760–762. 1 indexed citations

12.

Bergsland, Emily K., Thomas A. Hope, Pamela L. Kunz, et al.. (2018). P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. Journal of Thoracic Oncology. 13(10). S575–S575. 1 indexed citations

13.

Laidley, David, et al.. (2017). The Efficacy of PET-CT in Detecting Bone Marrow Involvement in Patients with Newly Diagnosed Lymphoma: A Retrospective Study. Blood. 130. 4160–4160. 1 indexed citations

14.

Cai, Yunliang, Mark Landis, David Laidley, et al.. (2016). Multi-modal vertebrae recognition using Transformed Deep Convolution Network. Computerized Medical Imaging and Graphics. 51. 11–19. 70 indexed citations

15.

Singh, Simron, L. Sylvia, Hagen F. Kennecke, et al.. (2016). Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treatment Reviews. 47. 32–45. 63 indexed citations

16.

Laidley, David, Frank S. Prato, John Butler, et al.. (2013). Description and assessment of a registration-based approach to include bones for attenuation correction of whole-body PET/MRI. Medical Physics. 40(8). 82509–82509. 27 indexed citations

17.

Laidley, David, John Butler, Robert T. Thompson, et al.. (2012). Three MRI-based attenuation correction methods for PET. 53. 374–374. 1 indexed citations

18.

Laidley, David, John Butler, Frank S. Prato, et al.. (2012). Performance of PET/MRI attenuation correction in an oncology population. 53. 1220–1220. 1 indexed citations

19.

Laidley, David, Frederick Colbourne, & Dale Corbett. (2005). Increased Behavioral and Histological Variability Arising From Changes in Cerebrovascular Anatomy of the Mongolian Gerbil. Current Neurovascular Research. 2(5). 401–407. 19 indexed citations

20.

Szymanska, Aleksandra, Jeff Biernaskie, David Laidley, Shirley Granter‐Button, & Dale Corbett. (2005). Minocycline and intracerebral hemorrhage: influence of injury severity and delay to treatment. Experimental Neurology. 197(1). 189–196. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact